Patel Anish

COO Patel sells 48,300 shares at $27.99 avg; post-transaction holding 215,011 shares (-18.3%). Stock up 52.7% in 30 days from $25.75 current.

Patel Anish, Chief Operating Officer, executed 2 separate sales totaling 48,300 shares for $1,351,762.20, reducing his stake by 18.3% to 215,011 shares post-transaction. The sales occurred at a blended average price of $27.99, while the stock currently trades at $25.75—reflecting a 2.4-point decline from the transaction prices. Notably, the stock has rallied 52.7% over the prior 30 days and trades within 1.0% of its 52-week high of $26.00, suggesting elevated valuation momentum at the time of sale. At the same-ticker level, Patel's 5 prior trades at ELVN show a 4-of-5 pattern of well-timed sales on the 90-day horizon, with his most recent sales on 2025-01-07 posting 90-day declines ranging from -26.0% to -27.4%. His cross-ticker track record across 7 open-market sales shows a 57.14% well-timed rate at the 90-day mark. These data points are offset by the company's unprofitability (net income: $-20,148,000.00 in the most recent full fiscal year), which provides fundamental context for the timing of insider sales.

COO Patel sells 28,367 shares at $24.18 blended average as stock down 9.7% in 30d, company unprofitable with -$23.2M net income.

Anish Patel, CHIEF OPERATING OFFICER, executed 4 separate sales totaling 28,367 shares for $685,868.44 on 2025-01-07 at a blended average price of $24.18, reducing his holdings from 365,011 to 336,644 shares (-7.8%). The current stock price of $21.74 is 26.4% below its 52-week high of $29.55, and the stock has fallen 9.7% over the past 30 days and 22.1% over the past 90 days. At the same-ticker level, Patel's three prior sales at ELVN (on 2024-07-12, 2024-07-15, and 2024-07-16) all showed positive 90-day returns, indicating those prior sales were poorly timed relative to subsequent price performance. The company's fundamental position is challenged: Enliven Therapeutics reported a negative $23.2M net income over its most recent full fiscal year, placing this sale in a context of both near-term equity weakness and sustained unprofitability. The magnitude of this sale (7.8% of pre-transaction holdings in a single day) during a period of significant stock decline and structural losses warrants attention to whether broader strategic or operational headwinds may be emerging.

COO Patel sells 50,000 shares (50.0K shares) at blended $25.06 across 3 transactions; stock near 52-week high ($25.10) despite -$22.7M net loss.

Anish Patel, Chief Operating Officer, conducted 3 separate sales totaling 50,000 shares for $1,252,826.10 over four trading days (July 12–16, 2024), at prices clustered tightly around $25.06. The sales reduced his post-transaction holdings to 344,027 shares, a 12.7% reduction. The timing merits attention: Enliven Therapeutics stock has surged 42.5% over the past 90 days and currently trades at $24.65, just 1.8% below the 52-week high of $25.10—exactly where the COO executed his largest and earliest sales. Concurrently, the company reported a -$22.7M net loss over its most recent full fiscal year. The sale of a significant stake by the COO while the stock approaches its annual peak, amid ongoing unprofitability, presents a pattern for investors to monitor in context of the company's growth trajectory and path to profitability.